+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Vol 16. Cancer Sensitizing Agents for Chemotherapy

  • ID: 5018881
  • Book
  • October 2020
  • Region: Global
  • 200 Pages
  • Elsevier Science and Technology
1 of 3

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 16, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field.

This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.

  • Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality
  • Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor
  • Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
Note: Product cover images may vary from those shown
2 of 3
1. Structure and function of ALK
2. ALK rearranged lung cancer: Treatment and outcome
3. Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
4. Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, Inflammatory Myofibroblastic Tumor)
5. Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy
6. Resistance mechanisms to ALK TKI in tumors other than lung cancer
7. Therapeutic strategies to overcome ALK resistance in lung cancer
8. Novel Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD
9. Drug combinations to enhance ALK TKI anti-tumor efficacy in Neuroblastoma
10. State of the art and future perspectives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Friboulet, Luc
Luc Friboulet, PhD, is ERC Principal Investigator and INSERM team leader at Gustave Roussy cancer campus. He studies the tumor adaptation to kinase inhibitors. Linked to a clinical trial named MATCH-R allowing collection of repeated biopsies in patients treated with ALK, ROS1, RET, EGFR, BRAF, FGFR inhibitors Dr. Friboulet characterizes the resistance mechanisms and establishes new laboratory models.
Note: Product cover images may vary from those shown
Adroll
adroll